ES2441468B1 - Composición farmacéutica sólida de resina de intercambio catiónico. - Google Patents

Composición farmacéutica sólida de resina de intercambio catiónico. Download PDF

Info

Publication number
ES2441468B1
ES2441468B1 ES201231270A ES201231270A ES2441468B1 ES 2441468 B1 ES2441468 B1 ES 2441468B1 ES 201231270 A ES201231270 A ES 201231270A ES 201231270 A ES201231270 A ES 201231270A ES 2441468 B1 ES2441468 B1 ES 2441468B1
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
exchange resin
solid pharmaceutical
catiónic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201231270A
Other languages
English (en)
Other versions
ES2441468A1 (es
Inventor
José Luis FÁBREGAS VIDAL
Joaquín GÓMEZ TOMÁS
Núria RUIZ XIVILLÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Rubio SA
Original Assignee
Laboratorios Rubio SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Rubio SA filed Critical Laboratorios Rubio SA
Priority to ES201231270A priority Critical patent/ES2441468B1/es
Priority to PCT/ES2013/070565 priority patent/WO2014020222A1/es
Priority to ES13777105T priority patent/ES2734557T3/es
Priority to EP13777105.1A priority patent/EP2881106B1/en
Priority to US14/419,372 priority patent/US9474714B2/en
Publication of ES2441468A1 publication Critical patent/ES2441468A1/es
Application granted granted Critical
Publication of ES2441468B1 publication Critical patent/ES2441468B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L25/00—Compositions of, homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Compositions of derivatives of such polymers
    • C08L25/02—Homopolymers or copolymers of hydrocarbons
    • C08L25/04—Homopolymers or copolymers of styrene
    • C08L25/06—Polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica sólida de resina de intercambio catiónico que permite la preparación de una suspensión estable de la resina en un vehículo acuoso, y presenta una buena facilidad de resuspensión de la misma en el caso de la formación de un sedimento. Dicha composición comprende hidroxipropilmetilcelulosa y almidón pregelatinizado como excipientes funcionales. También se refiere a una forma sólida para la administración oral que la comprende, a la utilización de la misma para la preparación de formas sólidas orales, y a dicha composición para su uso en el tratamiento de la hiperpotasemia.

Description



imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)



  1. imagen1
ES201231270A 2012-08-03 2012-08-03 Composición farmacéutica sólida de resina de intercambio catiónico. Active ES2441468B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201231270A ES2441468B1 (es) 2012-08-03 2012-08-03 Composición farmacéutica sólida de resina de intercambio catiónico.
PCT/ES2013/070565 WO2014020222A1 (es) 2012-08-03 2013-07-31 Composición farmacéutica sólida de resina de intercambio catiónico
ES13777105T ES2734557T3 (es) 2012-08-03 2013-07-31 Composición farmacéutica sólida de resina de intercambio catiónico
EP13777105.1A EP2881106B1 (en) 2012-08-03 2013-07-31 Solid pharmaceutical composition of cation exchange resin
US14/419,372 US9474714B2 (en) 2012-08-03 2013-07-31 Solid pharmaceutical composition of cation exchange resin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231270A ES2441468B1 (es) 2012-08-03 2012-08-03 Composición farmacéutica sólida de resina de intercambio catiónico.

Publications (2)

Publication Number Publication Date
ES2441468A1 ES2441468A1 (es) 2014-02-04
ES2441468B1 true ES2441468B1 (es) 2014-11-13

Family

ID=49378304

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201231270A Active ES2441468B1 (es) 2012-08-03 2012-08-03 Composición farmacéutica sólida de resina de intercambio catiónico.
ES13777105T Active ES2734557T3 (es) 2012-08-03 2013-07-31 Composición farmacéutica sólida de resina de intercambio catiónico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13777105T Active ES2734557T3 (es) 2012-08-03 2013-07-31 Composición farmacéutica sólida de resina de intercambio catiónico

Country Status (4)

Country Link
US (1) US9474714B2 (es)
EP (1) EP2881106B1 (es)
ES (2) ES2441468B1 (es)
WO (1) WO2014020222A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ732542A (en) * 2014-12-23 2023-02-24 Ardelyx Inc Compositions and methods for treating hyperkalemia
US9549947B2 (en) 2014-12-23 2017-01-24 Ardelyx, Inc. Pharmaceutical compositions for treating hyperkalemia
WO2023058038A1 (en) * 2021-10-08 2023-04-13 Sava Healthcare Ltd A composition and method for removing metal ions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3207494B2 (ja) 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
EP1004310B1 (en) 1997-06-20 2009-06-17 Ohkura Pharmaceutical Co., Ltd. Gelled composition
WO1999020285A1 (fr) * 1997-10-16 1999-04-29 Sanwa Kagaku Kenkyusho Co., Ltd. Preparations de gels contenant un polystyrenesulfonate
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20070248564A1 (en) 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
US20120107381A1 (en) * 2009-05-13 2012-05-03 Relypsa, Inc. Powder formulations of potassium-binding active agents
WO2011018801A2 (en) 2009-08-12 2011-02-17 Genepharm India Pvt Ltd Solid oral dosage form of ziprasidone
US20130203721A1 (en) * 2010-02-22 2013-08-08 Lupin Limited Taste-masked powder for suspension compositions of methylprednisolone

Also Published As

Publication number Publication date
US9474714B2 (en) 2016-10-25
EP2881106A1 (en) 2015-06-10
WO2014020222A1 (es) 2014-02-06
EP2881106B1 (en) 2019-05-01
ES2441468A1 (es) 2014-02-04
US20150174065A1 (en) 2015-06-25
ES2734557T3 (es) 2019-12-10

Similar Documents

Publication Publication Date Title
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
HRP20180591T1 (hr) Inhibitori kinaze serina ili treonina
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
ES2421956B1 (es) Nueva forma cristalina de sulfato de sitagliptina
JP2013014622A5 (es)
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.
BR112012028788A2 (pt) fabricação de grânulos sem ativos
ES2441468B1 (es) Composición farmacéutica sólida de resina de intercambio catiónico.
CL2016000788A1 (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016)
ES2484068B1 (es) Una composición farmacéutica que contiene ketamina y amitriptilina
EP2959908A4 (en) ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES
EP2959905A4 (en) ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES
EP2959906A4 (en) ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE
EP2959907A4 (en) ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE
ES2502140T1 (es) Comprimidos de liberación inmediata de rasagilina hemitartrato
ES2600132T9 (es) Procedimiento para la preparación de estructuras oligoméricas complejas
ES2526935B2 (es) Compuestos para el tratamiento de infecciones por Leishmania
ES2437270B1 (es) Derivados de dihidroindeno, su preparación y su uso como medicamentos
ES2643369T3 (es) Formulación farmacéutica oral de liberación modificada que contiene gliclazida
ES2468665B1 (es) Composición farmacéutica de sulfato de condroitina y celecoxib
ES2405259B1 (es) Uso del enantiómero (+)-c75 para el tratamiento de la obesidad.
CN302164420S (zh) 旅居车（2）
CN302080738S (zh) 前保险杠

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2441468

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141113